Genelux Strengthens Leadership With Appointment Of Dr. Jason Litten As CMO To Advance Late-Stage Trials Of Olvi-Vec

Genelux Corporation, a late clinical-stage immuno-oncology company, has announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. In this role, Dr. Litten will lead all clinical development and medical strategy as the company prepares for several pivotal milestones in the advancement of its lead candidate, Olvi-Vec.

Thomas Zindrick, President, CEO, and Chairman of the Board, said the company is pleased to welcome Dr. Litten, noting his strong strategic vision and dedication to improving patient outcomes. He highlighted Dr. Litten’s extensive experience in oncology drug development and his proven ability to guide complex clinical programs from early stages through late-stage trials. Zindrick added that Dr. Litten’s expertise will be critical as Genelux progresses toward key readouts in ovarian and lung cancer and works to realize the full clinical and commercial potential of Olvi-Vec as a best-in-class immunotherapy.

Dr. Litten brings more than two decades of experience across academia, major pharmaceutical companies, and biotechnology firms. He has overseen the design and execution of Phase 1 through Phase 4 clinical trials involving both liquid and solid tumors and has worked across biologics, small molecules, and cell therapies.

Before joining Genelux, Dr. Litten served as Chief Medical Officer at Chimeric Therapeutics, Ltd., where he advanced several first-in-human cell therapy programs targeting brain, gastrointestinal, and hematologic cancers. He previously held the same role at Artiva Biotherapeutics, Inc., where he established and led clinical development, operations, regulatory affairs, quality, and medical affairs. Earlier in his career, he held senior positions at Optera Therapeutics Corp., Juno Therapeutics, Inc., Clovis Oncology, Inc., and Amgen Inc., contributing to global oncology development strategies.

Dr. Litten earned his medical degree from Emory University School of Medicine and holds a bachelor’s degree in Finance and Economics from Cornell University. He completed his postdoctoral training in Pediatric Hematology and Oncology at the University of Texas Southwestern Medical Center in Dallas and is licensed as a physician and surgeon in California.

Dr. Litten said he is honored to join Genelux at a critical time for the company. He described Olvi-Vec as a promising therapeutic platform with potential across several tumor types and emphasized his commitment to advancing clinical strategy, supporting future regulatory efforts, and helping deliver new treatment options for patients with difficult-to-treat cancers.

As part of his appointment, Dr. Litten was granted an inducement stock option to purchase 275,000 shares of Genelux common stock under the company’s 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The option’s exercise price equals the closing price of the company’s shares on the date of grant. The award will vest over four years, with 25% vesting after one year and the remaining shares vesting monthly over the following 36 months, subject to continued service.